Skip to Content
Merck
  • Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid.

Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid.

The Journal of laryngology and otology (2008-02-07)
J B Van Rijswijk, E A M Mylanus
ABSTRACT

We present a patient with persistent hypertrophic skin surrounding the percutaneous implant of a bone-anchored hearing aid system, successfully treated with intralesional applied corticosteroids. Case report and review of the world literature concerning bone-anchored hearing aid implantation and intralesional applied corticosteroids for the treatment of hypertrophic scars and keloids. Eight weeks after revision surgery to reduce surplus skin and subcutaneous scar tissue overgrowing the abutment, skin and subcutaneous scar tissue overgrowth reoccurred. As an alternative to yet another surgical procedure, the hypertrophic skin was treated with intralesional injections of triamcinolone acetonide. Three weeks after the treatment, a satisfying result was seen, and no subsequent relapse was observed. To our knowledge, this is the first, photographically well documented case report of a patient with persistent hypertrophic skin surrounding a percutaneous bone-anchored hearing aid implant, successfully treated with intralesional applied corticosteroids.

MATERIALS
Product Number
Brand
Product Description

Triamcinolone acetonide, European Pharmacopoeia (EP) Reference Standard
USP
Triamcinolone acetonide, United States Pharmacopeia (USP) Reference Standard
Supelco
Triamcinolone acetonide, analytical standard
Triamcinolone acetonide for system suitability, European Pharmacopoeia (EP) Reference Standard